Improvements in patient-reported outcomes following initiation of dolutegravir- or low-dose efavirenz-based first-line antiretroviral therapy: A four-year longitudinal analysis in Cameroon (NAMSAL ANRS 12313 trial).
Marwân-Al-Qays BousmahCamelia ProtopopescuMireille Mpoudi-EtamePierrette Omgba BassegaGwenaëlle MaradanJustin OlingaMarie VarloteauxTamara Tovar-SanchezÉric DelaporteCharles KouanfackSylvie Boyernull nullPublished in: Journal of acquired immune deficiency syndromes (1999) (2023)
Although supporting the current WHO guidelines recommending DTG- and EFV400-based regimens as preferred and alternative first-line ART, further studies should investigate medium-term mental health outcomes in patients on DTG.
Keyphrases
- antiretroviral therapy
- patient reported outcomes
- hiv infected
- low dose
- hiv infected patients
- human immunodeficiency virus
- hiv aids
- hiv positive
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- clinical trial
- study protocol
- mental health
- preterm infants
- cross sectional
- high dose
- phase iii
- case control
- open label
- phase ii
- south africa
- hepatitis c virus
- preterm birth